UCSF receives $5M donation to develop AI-monitoring platform for clinical care

OmniaBio opens commercial manufacturing facility in Canada, bringing cell and gene therapies to patients

OmniaBio Inc. announced the opening of a new North American cell and gene therapy manufacturing and artificial intelligence center of excellence, which is now Canada’s largest contract development and manufacturing organization facility dedicated to CGT.

October 25, 2024

Vol.50 No.40

Clinical Roundup

East Alabama Medical Center, Inflo Health, ACR ImPower program collaboration boosts recommendations follow-up by 74%

Inflo Health, a leader in AI-driven radiology follow-up care orchestration, announced that it has qualified for the American College of Radiology’s Learning Network Vendor Partner designation on the heels of a successful collaboration that saw East Alabama Medical Center significantly improve recommendations follow-up rates.

October 25, 2024

Vol.50 No.40

In Brief

David Baker, Demis Hassabis, and John Jumper receive 2024 Nobel Prize in Chemistry

David BakerPhoto credit: Niklas Elmehed © Nobel Prize OutreachDemis HassabisPhoto credit: Niklas Elmehed © Nobel Prize OutreachJohn M. JumperPhoto credit: Niklas Elmehed © Nobel Prize OutreachDavid Baker, Demis Hassabis, and John M. Jumper received the 2024 Nobel Prize in Chemistry for their work in protein design and prediction.

October 11, 2024

Vol.50 No.38

In Brief

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

Four NCI-designated cancer centers—Dana-Farber Cancer Institute, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, and The Sidney Kimmel Comprehensive Cancer Center and Whiting School of Engineering at Johns Hopkins—have joined together and secured funding from AWS, Deloitte, Microsoft, and NVIDIA, to create the Cancer AI Alliance.

October 04, 2024

Vol.50 No.37

In Brief

Qure.ai completes $65M Series D funding round

Qure.ai has announced the completion of a $65 million Series D funding round. The investment will expedite expansion into the U.S. market and other countries, increase investment in foundational AI models, and enable complementary med-tech company acquisitions.

October 04, 2024

Vol.50 No.37

Clinical Roundup

Data validates multimodal AI biomarker’s ability to help inform treatment decisions omCSPC

New data validated a multimodal artificial intelligence-based biomarker’s ability to help inform treatment decisions for patients with oligometastatic castration-sensitive prostate cancer, including metastasis-directed therapy benefit.

October 04, 2024

Vol.50 No.37

UCSF receives $5M donation to develop AI-monitoring platform for clinical care

YOU MAY BE INTERESTED IN

OmniaBio opens commercial manufacturing facility in Canada, bringing cell and gene therapies to patients

East Alabama Medical Center, Inflo Health, ACR ImPower program collaboration boosts recommendations follow-up by 74%

David Baker, Demis Hassabis, and John Jumper receive 2024 Nobel Prize in Chemistry

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

Qure.ai completes $65M Series D funding round

Data validates multimodal AI biomarker’s ability to help inform treatment decisions omCSPC

Renew today!

Subscriber content

Login